219 related articles for article (PubMed ID: 1672268)
41. Prolactin decrease and shift to a normal-like isoform profile during treatment with quinagolide in a patient affected by an invasive prolactinoma.
Guido R; Valenti S; Foppiani L; De Martini D; Cossu M; Giusti M
J Endocrinol Invest; 1997 May; 20(5):289-93. PubMed ID: 9258810
[TBL] [Abstract][Full Text] [Related]
42. Prolactinomas in infertile women: clinical and endocrine characteristics before and after 24 months of treatment with bromocriptine.
Hajder M; Hajder E; Dervisefendic M; Samardzic R; Alic E
Med Arch; 2013; 67(3):181-4. PubMed ID: 23848038
[TBL] [Abstract][Full Text] [Related]
43. Hyperprolactinaemia in males: a heterogeneous disorder.
Walsh JP; Pullan PT
Aust N Z J Med; 1997 Aug; 27(4):385-90. PubMed ID: 9448878
[TBL] [Abstract][Full Text] [Related]
44. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.
Popovic V; Simic M; Ilic L; Micic D; Damjanovic S; Djurovic M; Obradovic S; Dieguez C; Casanueva F
Clin Endocrinol (Oxf); 1998 Jan; 48(1):103-8. PubMed ID: 9509075
[TBL] [Abstract][Full Text] [Related]
45. Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas.
Missale C; Losa M; Boroni F; Giovanelli M; Balsari A; Spano PF
Br J Cancer; 1995 Dec; 72(6):1397-9. PubMed ID: 8519650
[TBL] [Abstract][Full Text] [Related]
46. Rapid resolution of visual abnormalities with medical therapy alone in patients with large prolactinomas.
Mbanya JC; Mendelow AD; Crawford PJ; Hall K; Dewar JH; Kendall-Taylor P
Br J Neurosurg; 1993; 7(5):519-27. PubMed ID: 8267889
[TBL] [Abstract][Full Text] [Related]
47. Disappearance of a pituitary tumor after 15 months of treatment with CV 205-502, a new dopamine agonist.
Fassbender WJ; Stracke H; Bachmann G; Rau W; Federlin K
Clin Investig; 1992 May; 70(5):444-6. PubMed ID: 1350936
[TBL] [Abstract][Full Text] [Related]
48. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.
Chattopadhyay A; Bhansali A; Masoodi SR
Pituitary; 2005; 8(2):147-54. PubMed ID: 16379032
[TBL] [Abstract][Full Text] [Related]
49. Combination Treatment with Bromocriptine and Metformin in Patients with Bromocriptine-Resistant Prolactinomas: Pilot Study.
Liu X; Liu Y; Gao J; Feng M; Bao X; Deng K; Yao Y; Wang R
World Neurosurg; 2018 Jul; 115():94-98. PubMed ID: 29530699
[TBL] [Abstract][Full Text] [Related]
50. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
51. Effect of CV 205-502 in hyperprolactinaemic patients intolerant of bromocriptine.
Newman CB; Hurley AM; Kleinberg DL
Clin Endocrinol (Oxf); 1989 Oct; 31(4):391-400. PubMed ID: 2576397
[TBL] [Abstract][Full Text] [Related]
52. The long-term effects of pregnancy and bromocriptine treatment on prolactinomas--the value of radiologic studies.
Badawy SZ; Marziale JC; Rosenbaum AE; Chang JK; Joy SE
Early Pregnancy; 1997 Dec; 3(4):306-11. PubMed ID: 10086082
[TBL] [Abstract][Full Text] [Related]
53. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine.
Ciccarelli E; Miola C; Grottoli S; Avataneo T; Lancranjan I; Camanni F
J Clin Endocrinol Metab; 1993 Feb; 76(2):484-8. PubMed ID: 8432794
[TBL] [Abstract][Full Text] [Related]
54. Quinagolide in the management of prolactinoma.
Schultz PN; Ginsberg L; McCutcheon IE; Samaan N; Leavens M; Gagel RF
Pituitary; 2000 Dec; 3(4):239-49. PubMed ID: 11788012
[TBL] [Abstract][Full Text] [Related]
55. [Treatment of macroprolactinomas with quinagolide (Norprolac)].
Tabarin A; Catargi B
Ann Endocrinol (Paris); 1997; 58(2):87-94. PubMed ID: 9239226
[TBL] [Abstract][Full Text] [Related]
56. Depot-bromocriptine treatment for prolactinomas and acromegaly.
Grossman A; Ross R; Wass JA; Besser GM
Clin Endocrinol (Oxf); 1986 Feb; 24(2):231-8. PubMed ID: 3708874
[TBL] [Abstract][Full Text] [Related]
57. Discordant responses of prolactinoma to two different dopamine agonists.
Ahmed SR; Shalet SM
Clin Endocrinol (Oxf); 1986 Apr; 24(4):421-6. PubMed ID: 3742834
[TBL] [Abstract][Full Text] [Related]
58. Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years.
Haase R; Jaspers C; Schulte HM; Lancranja I; Pfingsten H; Orri-Fend M; Reinwein D; Benker G
Clin Endocrinol (Oxf); 1993 Feb; 38(2):165-76. PubMed ID: 8435897
[TBL] [Abstract][Full Text] [Related]
59. Dopamine receptor agonists for treating prolactinomas.
Colao A; di Sarno A; Pivonello R; di Somma C; Lombardi G
Expert Opin Investig Drugs; 2002 Jun; 11(6):787-800. PubMed ID: 12036422
[TBL] [Abstract][Full Text] [Related]
60. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
